Efficacy and Safety of the Combination of Docetaxel (Taxotere®) with Targeted Therapies in the Treatment of Solid Malignancies

Author(s): Vincenzo Emanuele Chiuri, Nicola Silvestris, Andrea Tinelli, Vito Lorusso

Journal Name: Current Drug Targets

Volume 10 , Issue 10 , 2009

Become EABM
Become Reviewer
Call for Editor


Docetaxel is a chemotherapeutic drug which has recently demonstrated high efficacy in the treatment of a wide variety of tumors. Numerous novel targeted drugs are being introduced in preclinical and clinical practice, aiming to directly inhibit pathways responsible for the maintenance of transformed and immortalized phenotypes of cancer cells. Herein we reported the efficacy and safety results of the most significant clinical trials evaluating different combinations and schedules of docetaxel plus biological therapeutics.

Keywords: Docetaxel, targeted therapy, solid tumors, EGFR, PDGFR, VEGFR, RTKI, BCL-2, safety, efficacy

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2009
Page: [982 - 1000]
Pages: 19
DOI: 10.2174/138945009789578007
Price: $65

Article Metrics

PDF: 4